There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

During the past decades, better understanding of relapsing-remitting multiple sclerosis
disease mechanisms have led to the development of several disease-modifying therapies …

Impaired manual dexterity is a frequently reported disability in people with multiple sclerosis
(MS) and is increasingly prevalent with worsening disease. While various tests and patient …

Multiple Sclerosis (MS) is a chronic autoimmune inflammatory disorder of the central
nervous system (CNS). Current therapies mainly target inflammatory processes during acute …

Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Multiple sclerosis is a major cause of neurological disability, which accrues predominantly
during progressive forms of the disease. Although development of multifocal inflammatory …

Background and purpose There is still no curative treatment for multiple sclerosis (MS), but
during the last 20 years eight different disease‐modifying compounds have been approved …

Background: Treatment with MD1003 (high-dose biotin) showed promising results in
progressive multiple sclerosis (MS) in a pilot open-label study. Objective: To confirm the …

A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …

Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …